A comparison of two medical-biomedical and genetics stocks reveals that Incyte (INCY) is the more attractive value investment option. INCY holds a Zacks Rank #2 (Buy) with improving earnings outlook and a Value grade of B, while Techne (TECH) has a Zacks Rank #3 (Hold) and Value grade of D. INCY's lower PEG ratio (2.67 vs 7.53) and P/B ratio (3.94 vs 5.38) suggest better valuation metrics.
TECH
Bio-Techne Corp. · NASDAQ
News
1 latestHeadlines link to the publisher. Not investment advice.